The information in this section is intended for visitors outside the United States.
Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent
Gilead Sciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13
Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals’ Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
2013 Annual Review